Log in

ASX:LCTLiving Cell Technologies Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.01
MA: A$0.02
A$0.02
52-Week Range N/A
Volume279,311 shs
Average VolumeN/A
Market Capitalization$7.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. Living Cell Technologies Limited was founded in 1987 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 8689 9997

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$708,094.00
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7.43 million
Next Earnings DateN/A
OptionableNot Optionable

Receive LCT News and Ratings via Email

Sign-up to receive the latest news and ratings for LCT and its competitors with MarketBeat's FREE daily newsletter.


Living Cell Technologies (ASX:LCT) Frequently Asked Questions

How were Living Cell Technologies' earnings last quarter?

Living Cell Technologies Ltd. (ASX:LCT) released its quarterly earnings data on Tuesday, February, 19th. The company reported $0.00 earnings per share for the quarter. View Living Cell Technologies' earnings history.

Has Living Cell Technologies been receiving favorable news coverage?

News headlines about LCT stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Living Cell Technologies earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutLiving Cell Technologies.

Who are some of Living Cell Technologies' key competitors?

What other stocks do shareholders of Living Cell Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Living Cell Technologies investors own include eWELLNESS HEALTHCARE (EWLL), Cheniere Energy (LNG), AllianceBernstein Global Hgh Incm Fd (AWF) and Energous (WATT).

Who are Living Cell Technologies' key executives?

Living Cell Technologies' management team includes the following people:
  • Dr. Kenneth Taylor, CEO & Exec. Director
  • Prof. Robert Elliott, Co-Founder & Director (Age 85)
  • Mr. Daya Uka, Chief Financial Officer
  • Mr. John Cowan, Head of Fin. & Admin. & Corp. Service Mang.
  • Dr. Janice Lam, Chief Operating Officer

What is Living Cell Technologies' stock symbol?

Living Cell Technologies trades on the ASX under the ticker symbol "LCT."

How big of a company is Living Cell Technologies?

Living Cell Technologies has a market capitalization of $0.00 and generates $708,094.00 in revenue each year.  View additional information about Living Cell Technologies.

What is Living Cell Technologies' official website?

The official website for Living Cell Technologies is http://www.lctglobal.com/.

How can I contact Living Cell Technologies?

The company can be reached via phone at 61 3 8689 9997.

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel